SCHEMBL4118107

SCHEMBL4118107

N#Cc1cccc(NC(=O)Nc2cccc(OC(F)F)c2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.63
▸ MAPT P10636 3/20 0.63
▸ KMT2A Q03164 3/20 0.63
▸ ALDH1A1 P00352 1/20 0.63
▸ GAA P10253 1/20 0.55
▸ ALOX15 P16050 1/20 0.55
▸ CASP7 P55210 1/20 0.55
▸ HSD17B10 Q99714 1/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ LMNA P02545 2/20 0.53
▸ HTT P42858 2/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ EPHX2 P34913 1/20 0.53
▸ GRM4 Q14833 3/20 0.51
▸ MCHR1 Q99705 1/20 0.50
▸ NSD2 O96028 1/20 0.50
▸ PPIA P62937 1/20 0.49
▸ PDK1 Q15118 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4116566 0.92 MAPT (0.68) MEN1MAPTKMT2AALDH1A1GAA
SCHEMBL4126167 0.91 MAPT (0.66) MEN1MAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL4106286 0.87 MAPT (0.65) MEN1MAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL4111082 0.86 MAPT (0.63) MEN1MAPTKMT2AALDH1A1GAA
SCHEMBL29580531 0.84 MAPT (0.87) MEN1MAPTKMT2AALDH1A1GAA
SCHEMBL30606801 0.84 MAPT (0.87) MEN1MAPTKMT2AALDH1A1GAA
SCHEMBL4118632 0.83 MAPT (0.64) MEN1MAPTKMT2AALDH1A1GAA
SCHEMBL4113827 0.81 MAPT (0.75) MEN1MAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL4124140 0.81 MEN1 (0.57) MEN1MAPTKMT2AALDH1A1HSD17B10
SCHEMBL533610 0.81 SLC6A2 (0.46) MEN1MAPTKMT2ALMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 — — US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 — — EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 — — WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 — — US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 — — US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MEN1 3273/4885MAPT 1654/4885KMT2A 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback